Horizon Technology Finance Provides $50 Million Venture Loan Facility to Pelthos Therapeutics
Horizon Technology Finance Corporation has provided a $50 million venture loan facility to Pelthos Therapeutics Inc., with $30 million initially funded and an additional $20 million available for future growth. The loan will support Pelthos' dermatology products ZELSUVMI and Xepi Cream, and the launch of Xeglyze, aiding in working capital and growth initiatives. Horizon's financing aligns with Pelthos' growth strategy, leveraging its expertise in lending to life science companies.
Horizon Technology Finance Corporation has announced the provision of a $50 million venture loan facility to Pelthos Therapeutics Inc., with an initial funding of $30 million and an additional $20 million available to support future growth. The facility is designed to help Pelthos promote its dermatology products ZELSUVMI and Xepi Cream, as well as support the launch of Xeglyze. The loan proceeds will be used for working capital and general growth initiatives. Horizon, known for its experience in lending to life science companies, structured the financing to align with Pelthos’ growth strategy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Horizon Technology Finance Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260115051163) on January 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)
